80 results about "Functional impairment" patented technology

Systems and methods for introducing one or more stimulating drugs and/or applying electrical stimulation to tissue affecting the penis to treat erectile dysfunction (for instance, following prostate surgery) uses at least one implantable system control unit (SCU) producing electrical pulses delivered via electrodes and/or producing drug infusion pulses, wherein the stimulating drug(s) are delivered via one or more pumps and infusion outlets.

A single, integrated device in which a body fluid (e.g., blood) of a human or animal can be both collected and analyzed easily and without risk of contamination is disclosed. The collection portion and analysis portion of the device are permanently joined to permit movement of small quantities of body fluid under controlled conditions, to minimize any waste of the body fluid, to ensure that no contamination reaches the main body fluid volume, and to create a permanent physical record of the results of the analysis in association with the fluid sample itself: A wide variety of different body fluid components which may be indicative of various diseases, dysfunctions and abnormalities of the human or animal or the body fluid itself can be tested for. The device includes a container for collecting human or animal body fluid, one or more testing chambers containing one or more analysis units activated by body fluid; a transfer pump or vacuum assembly to transfer one or more samples into the analysis units; and one-way valves or the equivalent to prevent any portion of the withdrawn sample from being returned to the collection container. The body fluid acted upon may be blood, blood plasma, urine, bile, pleural fluid, ascites fluid, stomach or intestine fluid, colostrom, milk or lymph.

This invention relates to compounds of formula I

their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R¹, R², R³ have meanings given in the description.

Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for intravitreal delivery of therapeutic gene constructs to retinal neuron cells, and specifically to ON bipolar cells, of the mammalian eye, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications including the treatment of retinitis pigmentosa, melanoma-associated retinopathy, and congenital stationary night blindness.

This invention relates to compounds of formula I

their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R¹, R², R³ have meanings given in the description.

This invention relates to compounds of formula I

their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R¹, R², R³ have meanings given in the description.

This invention relates to compounds of formula I

their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R¹, R², R³ have meanings given in the description.

A method is presented to address quantitative assessment of functional impairment in a subject, where the method comprises the steps of: (1) presenting a plurality of tests to a subject on a display, the plurality of tests comprising a series of scenes, the scene comprising at least one stimulus, wherein the scene may be associated with visual, auditory, and tactile stimulus arrays; (2) modulating at least one spatial characteristic of at least one stimulus; (3) receiving feedback from the subject via at least one input device; (4) quantitatively refining the scene relative to the received feedback; (5) calculating the relationship between at least one of the scene, the stimulus, and the quantitatively refined scene; (6) adjusting the scene relative to the calculated relationship; (7) determining equilibrated scene parameter of the subject; (8) recording the equilibrated scene parameter onto a tangible computer readable medium; (9) generating at least one diagnosis to the functional impairment associated with the equilibrated scene parameter; (10) recommending at least one treatment to the subject. An apparatus for quantitative assessment of functional impairment in a subject comprising an input device, a display device, a control device, and a tangible computer readable medium. A quantitative assessment profile of functional impairment by continuous modulation of specific perceptual domains on a stimulus and generating psychophysical responses on a tangible computer readable medium.

An alkyl ether derivative represented by the formula:

wherein R¹, R², R³, R⁴, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

A low-oscillation and space-saving drive for a changeable format folder of a rotary printing is provided, the rotary printing machine having rotating subassemblies that can be driven, in particular a cutting cylinder, a pin folding blade cylinder, a folding jaw cylinder, a gripper folding blade cylinder, and perforating cylinders belonging to a perforating device. The drive is split up into individual subsystems, and each subsystem is assigned a controlled-position drive motor. In the event of failure of a drive motor, the drive continues to operate without functional impairment.

The present invention provides compounds of formula I described herein. The present invention also provides a method of treating a cognitive dysfunction in a mammal. The method includes administering to the mammal an effective amount of a compound of formula I described herein (e.g., stearyl choline chloride).

Methods of using amino acid precursors of the serotonin and catecholamine neurotransmitter systems and laboratory urinary assay of serotonin and catecholamine neurotransmitter levels for optimal treatment of neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems. The methods may also include determining a urinary neurotransmitter phase response to a change in dosing of supplemental amino acid precursors of the serotonin and catecholamine neurotransmitters to optimally treat neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems.

Current medication labels are very difficult for people with disabilities, language barriers, functional impairments, or illiteracy to read, potentially increasing the risk for accidental medication overdoses and/or poor compliance with medication administration and adherence. By having a color coded sticker system with an enclosed full body guide in the form of a poster, and a home health medication record card, these stickers are placed on each medication bottle as a symbol for what the medication is used for. The stickers are color coded in order to distinguish the time the medication is to be administered. Home health agencies may use the poster and stickers as they educate their patients about the medications they take.